Neoplastic meningitis from solid tumors

New diagnostic and therapeutic approaches

Giuseppe Lombardi, Fable Zustovich, Patrizia Farina, Alessandro Della Puppa, Renzo Manara, Diego Cecchin, Antonella Brunello, Alessandro Cappetta, Vittorina Zagonel

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Neoplastic meningitis is a result of the spread of malignant cells to the leptomeninges and subarachnoid space and their dissemination within the cerebrospinal fluid. This event occurs in 4%-15% of all patients with solid tumors and represents an important prognostic factor for poor survival. Neoplastic meningitis should be diagnosed in the early stages of disease to prevent important neurological deficits and to provide the most appropriate treatment. Despite new diagnostic approaches developed in recent years, such as positron emission tomography-computed tomography and new biological markers, the combination of magnetic resonance imaging without and with gadolinium enhancement and cytology still has the greatest diagnostic sensitivity. Recently, no new randomized studies comparing intrathecal (i.t.) with systemic treatment have been performed, yet there have been a few small phase II studies and case reports about new molecularly targeted substances whose successful i.t. or systemic application has been reported. Trastuzumab, gefitinib, and sorafenib are examples of possible future treatments for neoplastic meningitis, in order to better individualize therapy thus allowing better outcomes. In this review, we analyze the most recent and interesting developments on diagnostic and therapeutic approaches.

Original languageEnglish
Pages (from-to)1175-1188
Number of pages14
JournalThe oncologist
Volume16
Issue number8
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Meningitis
Neoplasms
Therapeutics
Subarachnoid Space
Gadolinium
Cell Biology
Cerebrospinal Fluid
Biomarkers
Magnetic Resonance Imaging
Survival

Keywords

  • Brain tumors
  • Leptomeningeal carcinomatosis
  • Leptomeningeal disease
  • Neoplastic meningitis
  • Solid tumors
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Neoplastic meningitis from solid tumors : New diagnostic and therapeutic approaches. / Lombardi, Giuseppe; Zustovich, Fable; Farina, Patrizia; Puppa, Alessandro Della; Manara, Renzo; Cecchin, Diego; Brunello, Antonella; Cappetta, Alessandro; Zagonel, Vittorina.

In: The oncologist, Vol. 16, No. 8, 08.2011, p. 1175-1188.

Research output: Contribution to journalArticle

Lombardi, Giuseppe ; Zustovich, Fable ; Farina, Patrizia ; Puppa, Alessandro Della ; Manara, Renzo ; Cecchin, Diego ; Brunello, Antonella ; Cappetta, Alessandro ; Zagonel, Vittorina. / Neoplastic meningitis from solid tumors : New diagnostic and therapeutic approaches. In: The oncologist. 2011 ; Vol. 16, No. 8. pp. 1175-1188.
@article{4067da67578e4e77b78cb20f5ada3207,
title = "Neoplastic meningitis from solid tumors: New diagnostic and therapeutic approaches",
abstract = "Neoplastic meningitis is a result of the spread of malignant cells to the leptomeninges and subarachnoid space and their dissemination within the cerebrospinal fluid. This event occurs in 4{\%}-15{\%} of all patients with solid tumors and represents an important prognostic factor for poor survival. Neoplastic meningitis should be diagnosed in the early stages of disease to prevent important neurological deficits and to provide the most appropriate treatment. Despite new diagnostic approaches developed in recent years, such as positron emission tomography-computed tomography and new biological markers, the combination of magnetic resonance imaging without and with gadolinium enhancement and cytology still has the greatest diagnostic sensitivity. Recently, no new randomized studies comparing intrathecal (i.t.) with systemic treatment have been performed, yet there have been a few small phase II studies and case reports about new molecularly targeted substances whose successful i.t. or systemic application has been reported. Trastuzumab, gefitinib, and sorafenib are examples of possible future treatments for neoplastic meningitis, in order to better individualize therapy thus allowing better outcomes. In this review, we analyze the most recent and interesting developments on diagnostic and therapeutic approaches.",
keywords = "Brain tumors, Leptomeningeal carcinomatosis, Leptomeningeal disease, Neoplastic meningitis, Solid tumors, Targeted therapy",
author = "Giuseppe Lombardi and Fable Zustovich and Patrizia Farina and Puppa, {Alessandro Della} and Renzo Manara and Diego Cecchin and Antonella Brunello and Alessandro Cappetta and Vittorina Zagonel",
year = "2011",
month = "8",
doi = "10.1634/theoncologist.2011-0101",
language = "English",
volume = "16",
pages = "1175--1188",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "8",

}

TY - JOUR

T1 - Neoplastic meningitis from solid tumors

T2 - New diagnostic and therapeutic approaches

AU - Lombardi, Giuseppe

AU - Zustovich, Fable

AU - Farina, Patrizia

AU - Puppa, Alessandro Della

AU - Manara, Renzo

AU - Cecchin, Diego

AU - Brunello, Antonella

AU - Cappetta, Alessandro

AU - Zagonel, Vittorina

PY - 2011/8

Y1 - 2011/8

N2 - Neoplastic meningitis is a result of the spread of malignant cells to the leptomeninges and subarachnoid space and their dissemination within the cerebrospinal fluid. This event occurs in 4%-15% of all patients with solid tumors and represents an important prognostic factor for poor survival. Neoplastic meningitis should be diagnosed in the early stages of disease to prevent important neurological deficits and to provide the most appropriate treatment. Despite new diagnostic approaches developed in recent years, such as positron emission tomography-computed tomography and new biological markers, the combination of magnetic resonance imaging without and with gadolinium enhancement and cytology still has the greatest diagnostic sensitivity. Recently, no new randomized studies comparing intrathecal (i.t.) with systemic treatment have been performed, yet there have been a few small phase II studies and case reports about new molecularly targeted substances whose successful i.t. or systemic application has been reported. Trastuzumab, gefitinib, and sorafenib are examples of possible future treatments for neoplastic meningitis, in order to better individualize therapy thus allowing better outcomes. In this review, we analyze the most recent and interesting developments on diagnostic and therapeutic approaches.

AB - Neoplastic meningitis is a result of the spread of malignant cells to the leptomeninges and subarachnoid space and their dissemination within the cerebrospinal fluid. This event occurs in 4%-15% of all patients with solid tumors and represents an important prognostic factor for poor survival. Neoplastic meningitis should be diagnosed in the early stages of disease to prevent important neurological deficits and to provide the most appropriate treatment. Despite new diagnostic approaches developed in recent years, such as positron emission tomography-computed tomography and new biological markers, the combination of magnetic resonance imaging without and with gadolinium enhancement and cytology still has the greatest diagnostic sensitivity. Recently, no new randomized studies comparing intrathecal (i.t.) with systemic treatment have been performed, yet there have been a few small phase II studies and case reports about new molecularly targeted substances whose successful i.t. or systemic application has been reported. Trastuzumab, gefitinib, and sorafenib are examples of possible future treatments for neoplastic meningitis, in order to better individualize therapy thus allowing better outcomes. In this review, we analyze the most recent and interesting developments on diagnostic and therapeutic approaches.

KW - Brain tumors

KW - Leptomeningeal carcinomatosis

KW - Leptomeningeal disease

KW - Neoplastic meningitis

KW - Solid tumors

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=80052198656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052198656&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2011-0101

DO - 10.1634/theoncologist.2011-0101

M3 - Article

VL - 16

SP - 1175

EP - 1188

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 8

ER -